One Proven Drug and a Graveyard of Failed Alternatives: Vasospasm Prophylaxis After Aneurysmal SAH
An entire generation of drugs has reduced angiographic vasospasm without ever improving how the patient actually does — a striking, repeated pattern that leaves nimodipine standing alone, and raises the harder question of what a genuinely refractory case should reach for when the one proven drug isn't enough.
A.R., a 48-year-old woman who teaches high school chemistry and coaches the robotics team most afternoons, collapsed at home with the worst headache of her life, described by her husband as "nothing like anything I've ever seen her go through, and she's had migraines for twenty years." She lost consciousness briefly before EMS arrived and was found to have a ruptured anterior communicating artery aneurysm on CT angiography, Hunt-Hess grade III, modified Fisher grade 3. She has no significant past medical history beyond her longstanding migraines and takes no regular medications other than an occasional triptan.
The aneurysm was secured with endovascular coiling within twelve hours of presentation, and she is now on hospital day 4, entering the window — roughly days 4 through 14 after the bleed — when delayed cerebral ischemia from vasospasm poses its greatest risk. Nimodipine remains the only agent with proven improved neurological outcome in aneurysmal SAH, established across multiple randomized trials dating back to the 1980s, though its own mechanism of benefit is still debated: it does not clearly reduce angiographic vasospasm as much as it improves outcome, which has led some to propose a separate, direct neuroprotective effect independent of vessel diameter. Several other agents, tested specifically to improve on nimodipine's imperfect vasospasm-reduction profile, have failed outright: STASH found no benefit to simvastatin despite earlier observational promise, and MASH-2 found no benefit to magnesium sulfate despite a plausible mechanistic rationale involving smooth-muscle relaxation. Clazosentan, an endothelin-receptor antagonist, stands apart from those two: the CONSCIOUS trial program found it genuinely and repeatedly reduced angiographic vasospasm, a real pharmacologic effect the other failed candidates didn't reliably achieve — but it still did not improve clinical or functional outcome, and came with more pulmonary complications and hypotension than placebo. Her own course so far has been uncomplicated, transcranial Dopplers trending upward but not yet at a threshold most centers would call diagnostic of significant vasospasm, which is exactly the window where the team is discussing what, if anything, belongs in reserve if her course changes.
On rounds, day 4, entering the vasospasm-risk window
Nimodipine, full course, and that's the whole prophylaxis plan — 60mg every four hours, or 30mg every two if her pressure won't tolerate the standard dose. It remains the only agent with proven improved neurological outcome in this condition, across multiple trials going back decades, and it's worth flagging directly: its benefit doesn't track cleanly with reduced angiographic vasospasm, which suggests it's doing something more than just widening vessels on a scan.
Agreed on nimodipine as the backbone. What I'd want kept in reserve, though, is clazosentan, if she does progress to refractory symptomatic vasospasm despite that. The CONSCIOUS trials showed it genuinely and repeatedly reduces angiographic vasospasm — a real effect the statin and magnesium trials never managed. If we're out of other options in a deteriorating patient, I'd rather have tried something with a demonstrated mechanistic effect than nothing at all.
I'd push back on treating "reduces angiographic vasospasm" as a real partial win worth banking on, though. The same CONSCIOUS program that showed that reduction also found no improvement in clinical or functional outcome, and more pulmonary complications and hypotension than placebo. That's the specific, repeated pattern across this whole drug class — a surrogate imaging improvement that never translates into the outcome that actually matters, this time with a real added cost on top of it.
I wouldn't build clazosentan into routine prophylaxis planning at all. If she genuinely reaches refractory symptomatic vasospasm despite nimodipine and standard supportive measures, that's a real, separate, unresolved question worth revisiting then, on her actual numbers — not something to pre-commit to tonight based on a trial program whose own outcome data argues against it as routine practice.
Agreed: nimodipine continues for the full 21-day course, with blood pressure monitored to allow dose adjustment if hypotension limits the standard regimen. Transcranial Doppler monitoring continues on the standing schedule, with a lower threshold for repeat vessel imaging if her trend continues rising.
Not agreed: whether clazosentan deserves a defined place as rescue therapy if she progresses to refractory symptomatic vasospasm despite nimodipine and standard supportive care. The surgeon's position and the pharmacologist's position were both left standing rather than resolved, with the group agreeing only to revisit the question directly if and when that clinical scenario actually arises.